Compositions and methods for the treatment of cystic fibrosis
Disclosed herein are methods and compositions for treating, inhibiting, or ameliorating pulmonary infections, including cystic fibrosis. Aspects described herein relate to compositions including a saline solution and hypochlorite and methods of using these compositions alone or in combination with additional compounds, including antibiotics, an anti-inflammatories, bronchodilators, mucolytics, or oxygen therapy for treating, ameliorating, or inhibiting a pulmonary infection, including cystic fibrosis.
1. A method for treating a pulmonary infection in a subject, comprising:
administering to the subject a composition comprising:
0.9% saline solution; and
75 ppm hypochlorite,
wherein the saline solution comprises a salt, the salt comprising:
aluminum in an amount of about 103 ppm to about 126 ppm,
bromine in an amount of about 50 ppm to about 62 ppm,
calcium in an amount of about 1891 ppm to about 2311 ppm,
iron in an amount of about 74 ppm to about 90 ppm,
magnesium in an amount of about 1750 ppm to about 2138 ppm,
phosphorus in an amount of about 4.6 ppm to about 5.6 ppm,
potassium in an amount of about 1555 ppm to about 1901 ppm, and
strontium in an amount of about 29 ppm to about 35 ppm; and,
wherein the composition is administered in an amount sufficient to treat the pulmonary infection in the subject.
2. The method of claim 1 , further comprising administering an antibiotic agent, an anti-inflammatory agent, a bronchodilator, a mucolytic agent, or oxygen therapy to the subject.
3. The method of claim 1 , further comprising administering ivacaftor, lumacaftor, tezacaftor, or analogues, derivatives, or combinations thereof to the subject.
4. The method of claim 1 , wherein the composition is administered intranasally or by inhalation.
5. The method of claim 1 , further comprising reducing the presence of an infectious organism in the lung.
6. The method of claim 5 , wherein the infectious organism is Pseudomonas aeruginosa or Burkholderia cepacia.
7. The method of claim 5 , wherein reducing the presence of an infectious organism reduces a dependency on or use of an antibiotic therapy.
8. The method of claim 7 , wherein the antibiotic therapy is erythromycin, tobramycin, or vancomycin.
9. The method of claim 1 , further comprising reducing mucus viscosity.
10. The method of claim 9 , wherein reducing mucus viscosity clears mucus buildup.
11. The method of claim 9 , further comprising promoting oxidation of nucleic acid material and oxidation of trapped organic materials.
12. The method of claim 9 , wherein reducing mucus viscosity reduces a dependency on or use of a mucolytic agent.
13. The method of claim 12 , wherein the mucolytic agent is dornase alfa, denufosol, acetylcysteine, hypertonic saline, or ambroxol.
14. The method of claim 1 , further comprising enhancing cystic fibrosis transmembrane conductance regulator (CFTR) function in a lung, wherein enhancing CFTR function maintains a surface liquid interface required for proper cilia function.
15. The method of claim 1 , further comprising reducing lung inflammation.
16. The method of claim 15 , wherein reducing lung inflammation reduces the use of non-steroidal anti-inflammatory drugs (NSAIDs).
17. The method of claim 1 , further comprising generating nitric oxide in blood vessels.
18. The method of claim 17 , wherein generating nitric oxide stimulates endothelial nitric-oxide synthesis (NOS).
19. A method for treating a pulmonary infection in a subject, comprising:
administering to the subject an electrolyzed saline solution, the electrolyzed saline comprising a reactive oxygen species and a salt present in an amount of about 0.01% to about 1%, the salt comprising:
aluminum in an amount of about 103 ppm to about 126 ppm,
bromine in an amount of about 50 ppm to about 62 ppm,
calcium in an amount of about 1891 ppm to about 2311 ppm,
iron in an amount of about 74 ppm to about 90 ppm,
magnesium in an amount of about 1750 ppm to about 2138 ppm,
phosphorus in an amount of about 4.6 ppm to about 5.6 ppm,
potassium in an amount of about 1555 ppm to about 1901 ppm,
and strontium in an amount of about 29 ppm to about 35 ppm; and;
wherein the composition is administered in an amount sufficient to treat the pulmonary infection in the subject.
20. The method of claim 19 , wherein the reactive oxygen species comprises hypochlorite present in an amount of about 4 ppm to about 100 ppm.